Holen Sie sich die Stockscreener-App
5.93
2.47%
-0.15
Schlusskurs vom Vortag:
$6.08
Offen:
$6.12
24-Stunden-Volumen:
124.47K
Relative Volume:
0.43
Marktkapitalisierung:
$213.58M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-34.55M
KGV:
-5.3694
EPS:
-1.1044
Netto-Cashflow:
$-31.28M
1W Leistung:
+10.84%
1M Leistung:
+37.91%
6M Leistung:
+444.04%
1J Leistung:
+449.07%
1-Tages-Spanne:
$5.775
$6.17
1-Wochen-Bereich:
$5.35
$6.26
52-Wochen-Spanne:
$1.00
$6.9099
An 2 Therapeutics Inc Stock (ANTX) Company Profile
Firmenname
An 2 Therapeutics Inc
Sektor
Branche
Telefon
(650) 331-9090
Adresse
1300 EL CAMINO REAL, SUITE 100, MENLO PARK
Compare ANTX vs VRTX, REGN, ARGX, RVMD, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ANTX
An 2 Therapeutics Inc
|
5.93 | 177.56M | 0 | -34.55M | -31.28M | -1.1044 |
VRTX
Vertex Pharmaceuticals Inc
|
496.07 | 121.57B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
784.36 | 69.95B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
865.04 | 55.61B | 4.16B | 1.29B | 734.26M | 19.58 |
RVMD
Revolution Medicines Inc
|
205.15 | 39.98B | 742.00K | -1.37B | -1.07B | -7.0731 |
ONC
Beone Medicines Ltd Adr
|
348.27 | 33.81B | 5.76B | 514.49M | 1.10B | 4.4813 |
An 2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-08-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2024-08-09 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-07-03 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2024-04-02 | Hochstufung | JMP Securities | Mkt Perform → Mkt Outperform |
| 2024-02-13 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-02-12 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2024-02-12 | Herabstufung | JMP Securities | Mkt Outperform → Mkt Perform |
| 2024-02-12 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-01-04 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2022-07-18 | Fortgesetzt | Oppenheimer | Outperform |
Alle ansehen
An 2 Therapeutics Inc Aktie (ANTX) Neueste Nachrichten
MapLight Therapeutics stock tumbles 50% on mixed phase 2 schizophrenia data (MPLT:NASDAQ) - Seeking Alpha
4D Molecular Therapeutics (Nasdaq: FDMT) posts positive 2-year wet AMD data - Stock Titan
Intensity Therapeutics, Inc. Restarts Patient Treatment in the Randomized, Presurgical Triple Negative Breast Cancer Phase 2 Clinical Trial (INVINCIBLE-4 Study) - PR Newswire
TG Therapeutics (TGTX) Starts Phase 2 Briumvi Trial - Yahoo Finance
Chemomab Therapeutics and Precision Medicine Pioneer Scipher Medicine Announce Merger Agreement to Advance Nebokitug in an AI-Powered Phase 2 Trial in Rheumatoid Arthritis - GlobeNewswire
GX-03 Phase 2 signals guide new Stage 2 plan at Turn Therapeutics (NASDAQ: TTRX) - Stock Titan
Axsome Therapeutics Initiates FOCUS-2 Phase 3 Trial of - GlobeNewswire
Turn Therapeutics to Host Webcast Presenting Comprehensive Interim Analysis and Optimized Stage 2 Design for GX-03 in Atopic Dermatitis - Business Wire
Form 4 Spyre Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Nuo Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Apogee Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Vyne Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Monopar Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Tango Therapeutics Inc For: 2 July By Investing.com - Investing.com Nigeria
Form 4 Lineage Cell Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Form 4 Alaunos Therapeutics Inc For: 2 July By Investing.com - Investing.com UK
Form 4 VistaGen Therapeutics Inc For: 2 July By Investing.com - Investing.com Canada
Form 4 Oncotelic Therapeutics Inc For: 2 July By Investing.com - Investing.com India
Intellia Therapeutics, Inc. SEC Filing (Jul 2, 2026) - Stock Titan
Talawar Therapeutics and JATT II Acquisition Corp. Announce Definitive Business Combination Agreement to Create Publicly Listed Biotechnology Company Developing Potentially Best-in-Class Bispecifics for I&I Diseases - BioSpace
Gain Therapeutics (GANX) wins FDA IND clearance to start GT-02287 Phase 2 Parkinson’s trial - Stock Titan
Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress - Business Wire
Kymera Therapeutics (KYMR) Extends Rally On Sanofi Milestone And Lupus Data - StocksToTrade
BioRestorative Therapies Announces Completion of BRTX-100 - GlobeNewswire
Protagonist Therapeutics, Inc. Stock 12‑Month Price Target Raised to $119.15, Implies 2% Downside - TradingView
Akebia Therapeutics And 2 Other Promising Penny Stocks To Watch - simplywall.st
DiaMedica Therapeutics Announces First Patients Dosed in Phase 2 Trial of DM199 for the Treatment of Fetal Growth Restriction - Business Wire
SYRE Stock Climbs As TL1A Data Ignite Analyst Upgrades - StocksToTrade
APGE Stock Climbs As Street Backs Zumilokibart Momentum - StocksToTrade
Allarity Therapeutics to Present Trial-in-Progress Poster - GlobeNewswire
Edgewise Therapeutics Announces Positive Top-Line Data from 12-Week Phase 2 CIRRUS-HCM Trial with EDG-7500 in Obstructive and Nonobstructive Hypertrophic Cardiomyopathy (HCM) - PR Newswire
Elicio Therapeutics Reports Results from Phase 2 AMPLIFY-7P - GlobeNewswire
Lexeo Therapeutics Announces Regulatory Update and - GlobeNewswire
Enliven Therapeutics Stock Surges On ELVN-001 Breakthrough And $400M Raise - StocksToTrade
Rein Therapeutics Expands Phase 2 RENEW Trial into United Kingdom - GlobeNewswire
IPF trial for LTI-03 adds first UK patient, expands to 3 countries - Stock Titan
TGTX Stock Surges As Briumvi Pipeline Momentum Accelerates - StocksToTrade
Tectonic Therapeutic Completes Enrollment in TX45 APEX Phase 2 Clinical Trial in PH-HFpEF Patients - GlobeNewswire
TG Therapeutics Announces Positive Topline Phase 1 Data for - GlobeNewswire
Tango Therapeutics Announces Combination of Vopimetostat - GlobeNewswire
Structure Therapeutics (GPCR) Reports Positive Phase 2 Weight Loss Data for Aleniglipron - Yahoo Finance
AN2 Therapeutics Reports Positive Enabling Data Supporting Advancement of Oral AN2-502998 to Phase 2 Study for Chronic Chagas Disease - Business Wire
Vertex Pharmaceuticals Inc Stock (VRTX) Closed Down by 3.03% on Jun 2: Facts Behind the Movement - TradingKey
Convergent Therapeutics Announces Positive Phase 2 Data at ASCO 2026 Showing Promising Anti-Tumor Activity, Durability, and Favorable Tolerability for CONV01-α in Lu-PSMA-Exposed Metastatic Castration-Resistant Prostate Cancer (mCRPC) - Business Wire
Turn Therapeutics Reports Interim Analysis Findings and Adaptive Optimization Strategy from Phase 2 GX-03 Trial in Moderate-to-Severe Atopic Dermatitis - Business Wire
Avenzo Therapeutics Presents Updated Results from the Phase 1/2 Study of AVZO-021, a Potentially Differentiated CDK2 Inhibitor, at the 2026 American Society of Clinical Oncology Annual Meeting - Business Wire
Monopar Therapeutics Presents Phase 2 Data for ALXN1840 at EASL Congress 2026, Demonstrating Liver Disease Stabilization and Neurological Improvements in Wilson Disease Patients - Quiver Quantitative
Skyhawk Therapeutics Announces Twelve-Month Interim Results from Phase 1/2 Clinical Trial of SKY-0515 in Huntington's Disease - PR Newswire
Apogee Therapeutics, Inc. (APGE) Discusses Positive Part B Results From Phase 2 APEX Trial of Zumilokibart in Atopic DermatitisSlideshow (NASDAQ:APGE) 2026-05-30 - Seeking Alpha
Monopar Therapeutics (MNPR) shares Phase 2 Wilson disease data at EASL 2026 - Stock Titan
C4 Therapeutics, Inc. unveils Phase 2 trial progress for cemsidomide at ASCO26 - Traders Union
Finanzdaten der An 2 Therapeutics Inc-Aktie (ANTX)
Umsatz
Nettogewinn
Free Cashflow
ENV
An 2 Therapeutics Inc-Aktie (ANTX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Williams Sarah Joanne | Principal Accounting Officer |
May 29 '26 |
Sale |
4.43 |
265 |
1,174 |
66,583 |
| Williams Sarah Joanne | Principal Accounting Officer |
Mar 03 '26 |
Sale |
1.06 |
327 |
347 |
66,848 |
| Day Lucy | Chief Financial Officer |
Jan 06 '26 |
Sale |
1.01 |
5,512 |
5,578 |
75,363 |
| Day Lucy | Chief Financial Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
80,875 |
| Prior Stephen David | Chief Strategy Officer |
Jan 05 '26 |
Sale |
1.00 |
3,604 |
3,615 |
61,944 |
| Prior Stephen David | Chief Strategy Officer |
Jan 06 '26 |
Sale |
1.01 |
2,858 |
2,892 |
59,086 |
| Chanda Sanjay | Chief Development Officer |
Jan 06 '26 |
Sale |
1.01 |
5,956 |
6,027 |
75,823 |
| Chanda Sanjay | Chief Development Officer |
Jan 05 '26 |
Sale |
1.00 |
3,295 |
3,305 |
81,779 |
| Eizen Joshua M | See Remarks |
Jan 05 '26 |
Sale |
1.00 |
17,923 |
17,948 |
159,430 |
| Eizen Joshua M | See Remarks |
Jan 06 '26 |
Sale |
1.01 |
6,931 |
7,014 |
152,499 |
1.84%
0.86%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):